Grant: Fellowship - Priority Announcement - Inflammatory Bowel Disease
University of British Columbia
$45,000.00
The role of signalling pathways in maintaining T regulatory cell function
EF 2011-12
Résumé
Autoimmune diseases, such as inflammatory bowel disease, multiple sclerosis, rheumatoid arthritis and psoriasis, arise from an overactive immune response against substances and tissues normally present in the body. If this over reactivity against self persists for a long time it results in chronic inflammation. There are no known cures for autoimmune diseases; currently at best there are mildly alleviating treatments. For instance, patients with autoimmune diseases are typically given drugs to suppress the immune system to diminish immune responses in general. This type of treatment means that the individual becomes susceptible to infection and cancer as their immune system is effectively turned off.
My project focuses on an immune cell called a T regulatory cell (Treg), these cells have the ability to suppress immune responses and normally prevent autoimmune diseases. The way that Tregs turn immune responses off is not clearly understood, and the goal of my project is to discover how Treg cells work. In parallel, I will also study how they interact with other types of immune cells. Gaining a greater understanding of how the actions of Tregs are controlled will help to develop new therapies for diseases caused by an over active immune response thus reducing the dependency on non-specific immunosuppressive drugs. Each year there are over 800,000 new cases of Inflammatory bowel disease diagnosed, in Canada alone there are over 200,000 people suffer from this debilitating disease. Thus, this research aims to improve the quality of life for a significant part of the Canadian population.
Programme
Fellowship - Priority Announcement - Inflammatory Bowel Disease
Bénéficiaire
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
243162
Name
Patterson Scott
Region
British Columbia
Country
Canada
Orgtype
Research Institution; Institution Paid
Partnername
Canadian Association of Gastroenterology (Oakville, Ontario); Ferring Pharmaceuticals Inc. (North York, Ont.)
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
The role of signalling pathways in maintaining T regulatory cell function
Programtype2
Fellowship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$45,000
Cihrequipment2
$0
Programname2
Fellowship - Priority Announcement - Inflammatory Bowel Disease
Keyworddelim
Cellular Biology; In Vivo Mouse Models; Inflammatory Bowel Disease; Molecular Biology; Multiple Sclerosis; T Cell Immunology
Abstract
Autoimmune diseases, such as inflammatory bowel disease, multiple sclerosis, rheumatoid arthritis and psoriasis, arise from an overactive immune response against substances and tissues normally present in the body. If this over reactivity against self persists for a long time it results in chronic inflammation. There are no known cures for autoimmune diseases; currently at best there are mildly alleviating treatments. For instance, patients with autoimmune diseases are typically given drugs to suppress the immune system to diminish immune responses in general. This type of treatment means that the individual becomes susceptible to infection and cancer as their immune system is effectively turned off.
My project focuses on an immune cell called a T regulatory cell (Treg), these cells have the ability to suppress immune responses and normally prevent autoimmune diseases. The way that Tregs turn immune responses off is not clearly understood, and the goal of my project is to discover how Treg cells work. In parallel, I will also study how they interact with other types of immune cells. Gaining a greater understanding of how the actions of Tregs are controlled will help to develop new therapies for diseases caused by an over active immune response thus reducing the dependency on non-specific immunosuppressive drugs. Each year there are over 800,000 new cases of Inflammatory bowel disease diagnosed, in Canada alone there are over 200,000 people suffer from this debilitating disease. Thus, this research aims to improve the quality of life for a significant part of the Canadian population.
Competitiondate
201110
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Patterson, Scott
Approvedterm
2 ans 0 mois
Cihrcontribution2
Inst of Nutr Metabolism &Diab~ $45,000~ $0~